Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer

Additional Information

Published Date Mar 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3204
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Leukemia, Lymphoma and Pancreatic Cancer.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer.

    To find out more about Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Leukemia, Lymphoma and Pancreatic Cancer. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part III: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part III: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

This Report Includes the Following Companies:
3M Pharmaceuticals
4SC
AB Science
Abbott
Abiogen
Actinium Pharmaceuticals
Active Biotech
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Agenus
Aida Pharmaceuticals
Alexion
Alfa Wassermann
Alfacell
Allos Therapeutics
Altor BioScience
Ambit Biosciences
Amgen
Antisense Pharma
Antisoma
Anza Therapeutics
Apogee Biotechnology
Apotex
Apricus Biosciences
Arca biopharma
Ardea Biosciences
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Bayer
Benitec
Betapharma
Bio-Path Holdings
Biocon
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biolex
Bionovo
BioNumerik
BioSante
Bioton
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Callisto Pharmaceuticals
Cancer Advances
Cancer Research Technology
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
Choongwae
CJ Corp
Clavis Pharma
CompleGen
Cornerstone Pharmaceuticals
CritiTech
CSL
Curacyte
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DiaMedica
Dong-A
Dr Reddy’s
Dynavax Technologies
EGEN Inc
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
Favrille
FibroGen
Forma Therapeutics
Galectin Therapeutics
Gemin X Biotechnologies
Genencor
Genentech
Genmab
GenPat77
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
GlycoMimetics
Hanmi
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
IDM Pharma
IGF Oncology
IkerChem
ImClone Systems
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Incyte Corporation
InDex Pharmaceuticals
Inex
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Italfarmaco
Johnson & Johnson
Kadmon
KaloBios
Kanisa
Kinex
Kissei
Kyowa Hakko Kirin
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
MBiotec
Meda
MediGene
MedImmune
Medisyn Technologies
Memgen
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mologen
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novogen
Noxxon
Nycomed Pharma
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Patrys
Pepscan Therapeutics
Pfizer
Pharmacyclics
PharmaMar
Pharmexa
Philogen
PIERIS Proteolab
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Prochon Biotech
ProMetic Life Sciences
ProNAi Therapeutics
Protgen
Ras Therapeutics
Reata Pharmaceuticals
Regeneron
Regulon
Reliance Life Sciences
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Sareum
SBI Biotech
SBIO
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Sepal Pharma
Servier
Shenogen
Shire
Sidus
Southern Research Institute
Spirogen
Stemline Therapeutics
SuperGen
SuppreMol
Swedish Orphan Biovitrum
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
Synta Pharmaceuticals
Syntrix
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
Tau Therapeutics
TeGenero
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Titan Pharmaceuticals
TopoTarget
Tragara Pharmaceuticals
Transgene
Trion Pharma
UMN Pharma
Vaccinex
Valeant
VaxOnco
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
ViroMed
XBiotech
Xencor
Xerion
Yakult Honsha
Yamasa Corporation
YM BioSciences
Zenotech
Zenyaku Kogyo
Zeria
A Shortlist of Drugs Included are:
131I-tositumomab
AEG-35156
aflibercept
AGS-1C4D4
alemtuzumab
amonafide malate
amrubicin hydrochloride
amsacrine
apricoxib
ARC-100
ARQ-197
barasertib
bardoxolone methyl
belinostat
bevacizumab
bexarotene
bisantrene
bortezomib
bosutinib
brentuximab vedotin
brivanib alaninate
brivudine
Cabozantinib
capecitabine
catumaxomab
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
cladribine
clofarabine
conatumumab
CPI-613
CRLX-101
CSF-GM
cytarabine ocfosfate
cytarabine, injectable
dalotuzumab
dasatinib
daunorubicin
decitabine
denileukin diftitox
docetaxel
doxorubicin
E-7820
elacytarabine
elliptinium acetate
eniluracil
enocitabine
enzastaurin hydrochloride
epirubicin
erlotinib
everolimus
galiximab
ganitumab
gefitinib
gemtuzumab ozogamicin
GSK-1120212
GV-1001
GVAX
HBP-347
histamine dihydrochloride
ibritumomab tiuxetan
icotinib hydrochloride
idarubicin
imatinib mesilate
IMP-321
inotuzumab ozogamicin
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
ipilimumab
irinotecan
irinotecan hydrochloride
KD032
L19-IL2
lapatinib ditosylate
lestaurtinib
leukemia vaccine
LipoVIL12
lumiliximab
masitinib
MetXia
midostaurin
mitoxantrone
MKC-1
mocetinostat
motexafin gadolinium
nadroparin
nilotinib
nimotuzumab
obinutuzumab
oblimersen sodium
ofatumumab
olaparib
ON-01910
OTS-102
P-276-00
paclitaxel
PancAtak
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
peginterferon alfa-2b
pemetrexed disodium
pentamidine isethionate
pentostatin
perifosine
pixantrone
plitidepsin
pralatrexate
PX-12
razoxane
Reditux
Rexin-G
rhIFN-alpha
rituximab
romidepsin
RX-0201
selumetinib
siltuximab
sobuzoxane
sorafenib tosylate
ß-lapachone
sunitinib malate
talminogene laherparepvec
tamibarotene
tegafur + uracil
temsirolimus
teniposide
tigatuzumab
tipifarnib
tocilizumab
trabedersen
trastuzumab
triciribine phosphate
TS-1
tucotuzumab celmoleukin
varlitinib
vismodegib
volociximab
vosaroxin
WX-671
Z-360
zanolimumab
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer.
    To find out more about Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Lymphoma and Melanoma
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Lymphoma and Melanoma. Learn More


Triple Analysis: Pancreatic Cancer, Prostate Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Pancreatic Cancer and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Learn More

Other selected research from the 'Oncology' category:


Cancer Drugs in the FDA Fast Lane Drug Pipeline Update
BioSeeker Group have identified 142 companies plus partners who are today developing 171 cancer drugs in the FDA fast lane drugs in 1660 developmental projects in cancer across 177 different targets. In addition, there are 7 suspended drugs and another 65 drugs where development has been ceased. Learn More


Triple Analysis: Lymphoma, Melanoma and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More